Juniper Pharmaceuticals Inc (JNP): James A Geraghty , director of Juniper Pharmaceuticals Inc purchased 2,000 shares on Sep 13, 2016. The Insider buying transaction was reported by the company on Sep 14, 2016 to the Securities and Exchange Commission. The shares were purchased at $5.97 per share for a total value of $11,930.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 31, 2016, George Elston (CFO) purchased 1,000 shares at $5.50 per share price.On Aug 29, 2016, Alicia Secor (CEO) purchased 5,000 shares at $5.75 per share price.Also, On Aug 29, 2016, C Ann Merrifield (director) purchased 2,000 shares at $5.63 per share price.On Aug 24, 2016, Frank M Armstrong (director) purchased 1,623 shares at $6.16 per share price.
Juniper Pharmaceuticals Inc: On Monday, Sep 12, 2016 heightened volatility was witnessed in Juniper Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $5.5 and hit $5.95 on the upside , eventually ending the session at $5.81, with a gain of 2.83% or 0.16 points. The heightened volatility saw the trading volume jump to 6,453 shares. The 52-week high of the share price is $15.44 and the company has a market cap of $63 M . The 52-week low of the share price is at $4.3.
Company has been under the radar of several Street Analysts.Juniper Pharmaceuticals Inc is Downgraded by H.C. Wainwright to Neutral and the brokerage firm has set the Price Target at $6.75. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Aug 19, 2016.Juniper Pharmaceuticals Inc is Downgraded by Northland Capital to Market Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Aug 18, 2016.
Juniper Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women’s health. Juniper develops pharmaceutical products including CRINONE 8% (progesterone gel) which is marketed by Allergan Inc. in the United States and by Merck KGaA Darmstadt Germany in over 90 countries worldwide. The Company has in-house pharmaceutical development clinical trial manufacturing and analytical capabilities to advance its internal development pipeline including a 10% lidocaine bioadhesive vaginal gel in Phase IIb for gynecologic procedure-related pain and intra-vaginal rings for overactive bladder HRT and prevention of preterm birth while also providing consultative services to its pharmaceutical industry customers. Juniper Pharmaceuticals and Juniper Pharma Services are trademarks of the Company in the United States and European Union. CRINONE is a trademark of Allergan Inc. in the United States.